Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013

Novavax to Report Third Quarter 2013 Financial Results on November 7, 2013

ROCKVILLE, Md., Oct. 30, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX)
announced today that it will host a conference call and live webcast to report
its third quarter 2013 financial results on Thursday, November 7, 2013, at
4:30 p.m. ET.

The dial-in number for the conference call is 1 (877) 212-6076 (U.S. or
Canada) or 1 (707) 287-9331 (international). A webcast of the conference call
can also be accessed via a link on the home page of the Novavax website
(novavax.com) or through the "Investor Info"/"Events" tab on the Novavax
website.

A replay of the conference call will be available from 7:30 pm on November 7,
2013 until midnight December 6, 2013. To access the replay by telephone, dial
1 (855) 859-2056 (domestic) or 1 (404) 537-3406 (international) and use
passcode 93831495. The replay will also be available as a webcast and can be
found on the "Investor Info"/"Events" on the Novavax website.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant
protein nanoparticle vaccine technology, the company produces vaccine
candidates to efficiently and effectively respond to both known and newly
emergent diseases. Novavax is involved in several international partnerships,
including collaborations with Cadila Pharmaceuticals of India, LG Life
Sciences of Korea and PATH, and recently acquired Isconova AB, a leading
vaccine adjuvant company located in Sweden. Together, Novavax' network
supports its global commercialization strategy to create real and lasting
change in the biopharmaceutical and vaccinology fields. Additional information
about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000

Novavax logo